AstraZeneca

What science can do

AstraZeneca Annual Report and Form 20-F Information 2021

AstraZeneca at a Glance

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.

Our strategic priorities

Our Strategy and Key Performance Indicators, see from page 12.

Our priorities reflect how we are working to deliver our growth through innovation strategy and achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.

1. Accelerate Innovative Science
2. Deliver Growth and Therapy Area Leadership
3. Be a Great Place to Work

Science and innovation-led

Research & Development, see from page 32.

Development Pipeline Supplement, see www.astrazeneca.com/annualreport2021.

Distinctive R&D capabilities

We use our distinctive scientific capabilities to deliver a pipeline of life-changing medicines.

177
projects in our development pipeline



Phase I | Phase II | Late-stage development | Life-cycle management

[1] Includes Alexion.

Global R&D centres

Cambridge, UK

Gaithersburg, MD, US

Gothenburg, Sweden

Other R&D centres and offices
South San Francisco, CA, US
New York, NY, US
New Haven, CT, US
Boston, MA, US
Alderley Park and Macclesfield, UK
Shanghai, China
Osaka, Japan

A diversified portfolio with broad coverage across primary, specialty care and rare disease (Product Sales)

Disease Area Review, see from page 16 and Research & Development, see from page 32.

Oncology

We are leading a revolution in oncology to redefine cancer care.

$13,048m
36% of total
2020: $10,850m
2019: $8,667m

Sales growth of 20% (18% at CER)

BioPharmaceuticals

Creating a life without limits for billions of people living with chronic diseases.

Cardiovascular, Renal & Metabolism

$8,020m
22% of total
2020: $7,096m
2019: $6,906m

Sales growth of 13% (10% at CER)

Respiratory & Immunology

$6,034m
17% of total
2020: $5,357m
2019: $5,391m

Sales growth of 13% (9% at CER)

Rare Disease

Transforming the lives of people affected by rare diseases and devastating conditions.

$3,070m
8% of total

Revenue includes Alexion sales from 21 July 2021

Other Medicines

We have medicines and vaccines in other disease areas that have an important impact for patients.

$2,367m
6% of total
2020: $2,585m
2019: $2,601m

Sales decline of 8% (10% at CER)

COVID-19

Helping to change the course of the pandemic with our vaccine and a long-acting antibody.

$4,002m
11% of total
2020: $2m

Oncology. See from page 16.

BioPharmaceuticals. See from page 19.

Rare Disease. See from page 24.

Global strength, with balanced presence across regions (Product Sales)

Our Commercial Regions, see from page 36.

Product Sales by Disease Area



- Oncology 36%
- BioPharmaceuticals 38%
- Rare Disease 8%
- Other Medicines and COVID-19 17%

Product Sales by reporting region



- Emerging Markets 33%
- US 33%
- Europe 21%
- Established Rest of World 13%

Commitment to our people

A focus on inclusion and diversity, as well as lifelong learning and development.

People, see from page 41.

83,100
employees
2020: 76,100
2019: 70,600

48.1%
of our senior roles are filled by women

87%
of employees believe strongly in AstraZeneca's future direction and key priorities

78%
of employees believe there is effective collaboration between teams

Commitment to society

We recognise the interconnection between our business, the needs of society and the limitations of our planet. We are harnessing the power of science and innovation to deliver a positive impact to society, healthcare systems and the environment through actions for the long term.

Sustainability, see from page 44.

Priority **1**
Access to healthcare
Increasing access to life-saving treatments, promoting prevention, and strengthening global healthcare resilience and sustainability.

Priority **2**
Environmental protection
Accelerating the delivery of net-zero healthcare, managing our environmental impact, and investing in nature and biodiversity.

Priority **3**
Ethics and transparency
Ensuring ethical, open and inclusive behaviour across our organisation and value chain.

84%
of employees say they understand their contributions to our sustainability priorities.

access to medicine index
7th overall

CDP DRIVING SUSTAINABLE ECONOMIES
A List for Climate Change and Water Security

MEMBER OF Dow Jones Sustainability Indices In Collaboration with RobecoSAM
World and Europe constituent

GLOBAL100
Global 100 Most Sustainable Corporations in the World 2021

Capital allocation priorities

After providing for reinvestment in the business, supporting the progressive dividend policy and maintaining a strong, investment-grade credit rating, we keep under review potential investment in value-enhancing opportunities.

Financial Review, see from page 52.

Dividends
$3,856m
2020: $3,572m
2019: $3,592m

R&D expenditure (Reported)
$9,736m
2020: $5,991m
2019: $6,059m

Credit rating (Standard & Poor's)
A-
Long term:
Stable outlook

Credit rating (Moody's)
A3
Long term:
Negative outlook